As shown in a NSCLC CDX model, Msln-CCR4-CAR T cells enhanced infiltration and migration into tumor tissue, along with superior anti-tumor function and high levels of proinflammatory cytokines, including IL-2, IFN-γ, and TNF-α, suggesting that CAR T cells modified with chemokine receptor could be a potential strategy to promote T cell entry (67). The gene discussed is IL2; the disease is neoplasm.